Abstract:Abstract Background: Influenza virus matrix protein M1 is encoded by viral RNA fragment 7 and is the most abundant protein in virus particles. M1 is expressed in the late stages of viral replication and exerts functionality by inhibiting viral transcription. The M1 protein sequence is an attractive target for antibody drugs. Methods: The M1 protein sequence was amplified by RT-PCR using cDNA from the H5N1 virus as a template; the M1 protein was then expressed and purified. A human strain, high affinity, and single chain antibody (HuScFv) against M1 protein was obtained by phage antibody library screening using M1 as an antigen. A recombinant TAT-HuScFv protein was expressed by fusion with the TAT protein transduction domain (PTD) gene of HIV to prepare a human intracellular antibody against avian influenza virus. The differences between HuScFv and TAT-HUScFv were verified by various experiments and the amino acid binding site of the M1 protein was determined. Results: The M1 protein of H5N1, HuScFv, and TAT-HuScFv, were successfully purified and expressed by and in E. coli . Further analysis demonstrated that TAT-HuScFv inhibited the hemagglutination activity of the 300TCID 50 H1N1 virus, thus providing preliminary validation of the universality of the antibody. After two rounds of M1 protein decomposition, the TAT-HuScFv antigen binding site was identified as Alanine (A) at position 239. Collectively, our data describe a recombinant antibody with high binding activity against the conserved sequences of avian influenza viruses. This intracellular recombinant antibody blocked the M1 protein that infected intracellular viruses, thus inhibiting the replication and reproduction of H5N1 viruses. Conclusion: Recombinant HuScFv was successfully identified using the Tomlinson (I+J) phage antibody library and successfully linked to the TAT protein transductive domain of the HIV virus. Compared with the HuScFv, the addition of the TAT peptide improved its ability to penetrate the cell membrane. A definite amino acid binding site was identified after the decomposition of M1 protein, thus providing a target and reference for the development of antibody drugs and the study of new drugs.

Induction of Cross-Reactive Antibodies Against Mimotopes of H5N1 Hemagglutinin

Identification and Analysis of B Cell Epitopes of Hemagglutinin of H1N1 Influenza Virus.

Generation and Characterization of Monoclonal Antibodies Against the Hemagglutinin of H3N2 Influenza A Viruses.

Identification of a cross-neutralizing antibody that targets the receptor binding site of H1N1 and H5N1 influenza viruses

A Human Antibody Recognizing a Conserved Epitope of H5 Hemagglutinin Broadly Neutralizes Highly Pathogenic Avian Influenza H5N1 Viruses

Identification and Structural Characterization of a Broadly Neutralizing Antibody Targeting a Novel Conserved Epitope on the Influenza Virus H5N1 Hemagglutinin

Generation of Neutralizing and Non-Neutralizing Monoclonal Antibodies Against H7N9 Influenza Virus.

Development and biochemical characterization of the monoclonal antibodies for specific detection of the emerging H5N8 and H5Nx avian influenza virus hemagglutinins

Broadly cross-reactive mimotope of hypervariable region 1 of hepatitis C virus derived from DNA shuffling and screened by phage display library.

Conserved sites on the influenza H1 and H3 hemagglutinin recognized by human antibodies

Identification of a universal antigen epitope of influenza A virus using peptide microarray

Identification of specific neutralizing antibodies for highly pathogenic avian influenza H5 2.3.4.4b clades to facilitate vaccine design and therapeutics

A Critical HA1 Neutralizing Domain of H5N1 Influenza in an Optimal Conformation Induces Strong Cross-Protection

A high-affinity CDR-grafted antibody against influenza A H5N1 viruses recognizes a conserved epitope of H5 hemagglutinin.

Identification of antigenic epitopes in the haemagglutinin protein of H7 avian influenza virus

Human neutralizing antibodies target a conserved lateral patch on H7N9 hemagglutinin head

Complementary Recognition of the Receptor-Binding Site of Highly Pathogenic H5N1 Influenza Viruses by Two Human Neutralizing Antibodies

Site-Specific Glycan-Masking/Unmasking Hemagglutinin Antigen Design to Elicit Broadly Neutralizing and Stem-Binding Antibodies Against Highly Pathogenic Avian Influenza H5N1 Virus Infections

An Intracellular Human Single Chain Antibody to Matrix Protein (M1) of H5N1 Virus

Identification of key antigenic sites in hemagglutinin of H10N3 avian influenza virus

Neutralizing antibody PR8‐23 targets the footprint of the sialoglycan receptor binding site of H1N1 hemagglutinin